Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of effectiveness and complications of rituximab versus fingolimod for disability and motor function in multiple sclerosis
IRCT20130812014333N125Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rituximab and fingolimod in multiple sclerosis (MS) (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoint: Improvement in disability and motor function. Started May 2018; status: completed.
02
Drugs
rituximabfingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20130812014333N125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130812014333N125.